Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda

Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L. Joloba, Susan Adakun, Lydia Nakiyingi, Gabriela Torrea, Bruce J. Kirenga

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Abstract

Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.

We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.

Original languageEnglish
Article number100286
JournalJournal of Clinical Tuberculosis and Other Mycobacterial Diseases
Volume25
Number of pages5
ISSN2405-5794
DOIs
Publication statusPublished - 2021

Keywords

  • XpertMTB/RIF
  • G4
  • ULTRA
  • Rifampicin
  • Discordance
  • MYCOBACTERIUM-TUBERCULOSIS
  • RESISTANCE

Cite this